The artificial pancreas is an imprecise term that can mean a bioengineered product, such as an islet cell transplant, gene therapy to replace the pancreas, or the combination of a continuous glucose sensor, an insulin pump (with or without a glucagon pump), and a computer with an algorithm to control the delivery of insulin. In this chapter, we will consider only the last. This is an exciting topic with products being developed by an unusual consortium of academics, the JDRF, the NIH, the FDA, the Helmsley Foundation, and medical device companies. The first artificial pancreas was approved by the FDA in October of 2016 and was first marketed in June 2017 .
KeywordsArtificial pancreas Insulin pump Continuous glucose monitoring Proportional integrative derivative controllers Model predictive controllers Fuzzy logic controllers Cybersecurity
Continuous glucose monitoring system
US Food and Drug Administration
Apple operating system
Model predictive control. A controller algorithm
Proportional integral derivative. A controller algorithm
- 6.Lunze K, Singh T, Walter M, Brendel M, Leonhardt S. Blood glucose control algorithms for type 1 diabetic patients: a methodological review. Biomed Signal Process Control. https://doi.org/10.2016/j.bspc.2012.9.003. Accessed 12/30/2016.
- 8.FDA. The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems. 2012.Google Scholar
- 9.Yuan S, Fernando A, Klonoff DC. Standards for Medical Device Cybersecurity in 2018. https://doi.org/10.1177/1932296818763634. Accessed 25 April 2019.